Regenxbio to resubmit Hunter syndrome gene therapy without new study
Regenxbio said that it plans to resubmit its Hunter syndrome gene therapy following another apparent walk back by the FDA after leadership departures. According...
Regenxbio said that it plans to resubmit its Hunter syndrome gene therapy following another apparent walk back by the FDA after leadership departures. According to Regenxbio, the FDA told the biotech that its existing data ...